Medical devices, healthcare technology and the business of care
PMA approval · P230019

MediBeacon Transdermal GFR Measurement System (TGFR)

Medibeacon, Inc. · Decision date Jan 17, 2025

FDA DECISIONP230019

What did the FDA approve?

FDA records P230019 as an original PMA application. The recorded decision is approval, dated Jan 17, 2025.

FDA approval order statement

Approval for the MediBeacon Transdermal GFR System (TGFR) intended to assess the Glomerular Filtration Rate (GFR) in adult patients with impaired or normal renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent over time. This device has been validated in patients with stable renal function.The MediBeacon TGFR is not approved for use in patients with GFR <15 ml/min/1.73 m2, GFR >120 ml/min/1.73m2, patients on dialysis, or anuric patients. The use of this device in patients with dynamic and rapidly changing renal function has not been validated. This device is not intended to diagnose acute kidney injury (AKI).The MediBeacon TGFR Sensor and exogenous tracer agent, Lumitrace injection, are single use and are only used with the MediBeacon TGFR. The MediBeacon TGFR Sensor is a single use device intended to attach to the patient's skin and excite fluorescence in Lumitrace injection, the tracer agent, and measure the returning light intensity. The data is sent to the MediBeacon TGFR Monitor. Lumitrace is an injectable exogenous fluorescent tracer indicated for use with the MediBeacon Transdermal GFR System (TGFR) for Glomerular Filtration Rate assessment.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Jan 17, 2025

FDA source record

Regulatory record facts

Identifier
P230019
Regulatory pathway
Premarket approval application
Product code
SDK
Decision code
APPR
Decision date
Jan 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transdermal test for Assessment of Glomerular Filtration Rate.

Product code
SDK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230019 received

    Application receipt date recorded by FDA.

  2. P230019 · FDA decision

    APPR

  3. P230019/S005 · Related supplement

    MediBeacon Transdermal GFR System

Timeline entries are records held by MedtechLedger for P230019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230019

Product / regulatory recordCompanyPathwayDecision dateSource
Medibeacon, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medibeacon, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
425 N. New Ballas Rd., Suite 100, St. Louis, MO, 63141

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records